Issue 14, 2024

An immunogenic anti-cancer stem cell bi-nuclear copper(ii)-flufenamic acid complex

Abstract

An asymmetric bi-nuclear copper(II) complex with both cytotoxic and immunogenic activity towards breast cancer stem cells (CSCs) is reported. The bi-nuclear copper(II) complex comprises of two copper(II) centres bound to flufenamic acid and 3,4,7,8-tetramethyl-1,10-phenanthroline. The bi-nuclear copper(II) complex exhibits sub-micromolar potency towards breast CSCs grown in monolayers and three-dimensional cultures. Remarkably, the bi-nuclear copper(II) complex is up to 25-fold more potent toward breast CSC mammospheres than salinomycin (a gold standard anti-breast CSC agent) and cisplatin (a clinically administered metallodrug). Mechanistic studies showed that the bi-nuclear copper(II) complex readily enters breast CSCs, elevates intracellular reactive oxygen species levels, induces apoptosis, and promotes damage-associated molecular pattern release. The latter triggers phagocytosis of breast CSCs by macrophages. As far as we are aware, this is the first report of a bi-nuclear copper(II) complex to induce engulfment of breast CSCs by immune cells.

Graphical abstract: An immunogenic anti-cancer stem cell bi-nuclear copper(ii)-flufenamic acid complex

Supplementary files

Article information

Article type
Paper
Submitted
07 Feb 2024
Accepted
05 Mar 2024
First published
07 Mar 2024
This article is Open Access
Creative Commons BY license

Dalton Trans., 2024,53, 6410-6415

An immunogenic anti-cancer stem cell bi-nuclear copper(II)-flufenamic acid complex

Y. Li, J. Fang, K. Singh, F. Ortu and K. Suntharalingam, Dalton Trans., 2024, 53, 6410 DOI: 10.1039/D4DT00384E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements